Cost-effectiveness of roflumilast as an add-on to triple inhaled therapy vs triple inhaled therapy in patients with severe and very severe COPD associated with chronic bronchitis in the UK.

A reduction in the rate of moderate-to-severe exacerbations was observed, but did not reach statistical significance. 9 , 10 Although the rates of adverse events were higher in the roflumilast group than in the placebo group in both trials, mortality was similar.

also in 111,027 other papers